ArticleCancer science2025

Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer.

Masaru Tani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.